Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 8/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613029 | 0.83 | FEN1 (0.39) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL25613025 | 0.80 | FEN1 (0.37) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL25613171 | 0.80 | RIPK1 (0.39) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL25613108 | 0.80 | ULK1 (0.39) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL25613026 | 0.80 | FEN1 (0.42) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL25625104 | 0.79 | ULK1 (0.45) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL16982068 | 0.77 | FEN1 (0.36) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL19367958 | 0.77 | FEN1 (0.36) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL19367715 | 0.77 | CDK8 (0.34) | CDK8AXLFEN1KDRFGFR1 | |
| SCHEMBL25613169 | 0.77 | BRD4 (0.40) | CDK8AXLFEN1KDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-9782407-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9040558-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-05-26 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-7638530-B2 | 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents | MERCK & CO., INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | CDK8 4699/4885AXL 4864/4885FEN1 2065/4885 |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, MTTP | CDK8 4819/4885AXL 4873/4885FEN1 2577/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | CDK8 2811/4885AXL 1396/4885FEN1 3033/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | CDK8 4699/4885AXL 4864/4885FEN1 2065/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | CDK8 2748/4885AXL 1050/4885FEN1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.